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Abstract
Background: Elevated baseline C-reactive protein (CRP) levels are associated with increased risk
for developing cardiovascular disease. Several CRP gene variants have been associated with altered
baseline CRP levels in ambulatory populations. However, the influence of CRP gene variants on CRP
levels during inflammatory states, such as surgery, is largely unexplored. We describe the
association between candidate CRP gene variants and postoperative plasma CRP levels in patients
undergoing primary, elective coronary artery bypass graft (CABG) surgery with cardiopulmonary
bypass (CPB).
Methods:  Using a multicenter candidate gene association study design, we examined the
association between seventeen candidate CRP single nucleotide polymorphisms (SNPs) and inferred
haplotypes, and altered postoperative CRP levels in 604 patients undergoing CABG surgery with
CPB. Perioperative CRP levels were measured immediately prior to surgery, post-CPB and on
postoperative days (POD) 1–4.
Results: CRP levels were significantly elevated at all postoperative time points when compared
with preoperative levels (P < 0.0001). After adjusting for clinical covariates, the minor allele of the
synonymous coding SNP, rs1800947 was associated with lower peak postoperative CRP levels (P
= 2.4 × 10-4) and lower CRP levels across all postoperative time points (P = 4.8 × 10-5). rs1800947
remained highly significant after Bonferroni adjustment for multiple comparisons.
Conclusion: We identified a CRP gene SNP associated with lower postoperative CRP levels in
patients undergoing CABG surgery with CPB. Further investigation is needed to clarify the
significance of this association between CRP gene variants and the acute-phase rise in postoperative
CRP levels with regard to the risk of adverse postoperative outcomes.
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Background
Human CRP is a highly conserved protein belonging to
the pentraxin family of acute phase reactants. Normal
baseline plasma CRP levels are ≤1 mg/L in healthy indi-
viduals[1]. However, as an acute-phase reactant synthe-
sized in the liver, plasma CRP levels can rise 1000-fold in
response to tissue injury or inflammation[2,3], thereby
triggering activation of the classical complement path-
way[4,5], endothelial cell surface adhesion molecule
expression[6], leukocyte and macrophage activation, as
well as platelet adhesion[1,7]. The pro-inflammatory
effects of CRP may explain the increased risk of develop-
ing cardiovascular disease (CVD) associated with persist-
ently elevated baseline CRP levels [8-12].
Environmental factors such as age, gender, smoking, lipid
levels, hypertension and body mass index (BMI) have
been shown to influence baseline plasma CRP levels in
the absence of overt inflammatory stimuli[8,13]. Recent
family and population-based cohort studies have found
moderate heritability of baseline CRP levels [14-16].
There is now convincing evidence to support the associa-
tion between CRP gene variants and baseline plasma CRP
levels, and CVD in ambulatory populations [17-19]. Fur-
thermore, two recently published genome wide associa-
tion studies have identified several genes, including the
CRP gene, that influence basal CRP levels[20,21]. How-
ever, little is known about the influence of CRP gene vari-
ants on the acute-phase response of plasma CRP levels.
We therefore examined the association between candidate
CRP gene variants and postoperative plasma CRP levels
following primary, elective coronary artery bypass graft
(CABG) surgery with cardiopulmonary bypass (CPB).
Methods
Study design and population
A candidate gene association study was undertaken to
examine the association between CRP gene variants and
postoperative plasma CRP levels following CABG surgery
with CPB. One thousand eighty-two patients scheduled
for primary, elective CABG surgery at the Brigham and
Women's Hospital, Boston, MA and the Texas Heart Insti-
tute, St Luke's Episcopal Hospital, Houston, TX between
August 2001 and June 2007 were eligible for analysis. Fol-
lowing Institutional Review Boards approval, informed
consent was obtained from each patient prior to enroll-
ment. Exclusion criteria were defined prior to statistical
analysis in order to exclude patients with ongoing preop-
erative myocardial injury or other acute inflammatory
processes that may have confounded the relationship
between CRP variants and postoperative CRP level. Exclu-
sion criteria included age <20 years (n = 0), recent (<2
weeks) myocardial infarction (MI) by patient history (n =
207), preoperative white blood cell count >10.0/mm3 (n
= 255), preoperative cardiac troponin I (cTnI) level >0.17
ng/mL (n = 220), and recipients of leukocyte-rich blood
products within 30 days prior to surgery (n = 15). We
excluded eight patients with a preoperative acute inflam-
matory process and elevated CRP levels (> 60 mg/L).
Study protocol
Preoperative demographic data, environmental risk fac-
tors and perioperative surgical and anesthetic manage-
ment were recorded for all patients. Genomic DNA was
isolated from whole blood samples using standard tech-
niques[22]. Plasma CRP concentrations were measured
with a competitive format immunoassay, using a mono-
clonal antibody and labeled CRP, configured on Biosite's
Triage device platform (Biosite Inc., San Diego, CA), from
plasma drawn at six time points: preoperatively, immedi-
ately after termination of CPB, and on the mornings of
postoperative days (POD) 1–4. CRP concentrations were
calculated using a set of spiked plasma samples as the cal-
ibration reference. The analytical sensitivity of the CRP
assay is 0.33 μg/mL with precision of 17% over the meas-
urable range of the assay (0.33 – 300 μg/mL).
Candidate SNP identification and genotyping
In an effort to characterize the CRP  gene and the sur-
rounding region, we genotyped CRP single nucleotide
polymorphisms (SNPs) previously described in the litera-
ture[23]. In addition, we genotyped tagging SNPs for the
region encompassing the CRP gene including 3000 bp
upstream of the transcription start site and 1000 bp down-
stream of the 3' untranslated region (UTR). Tagging SNPs
with minor allele frequencies (MAF) >1% were identified
using Tagger based on a pairwise r2 tagging threshold of
0.8 (rs3316653, rs3316654, rs2794517, rs3122012,
rs3093058, rs2808630, rs3093077, rs2794520, rs876538,
rs876537, rs1572970)[24]. Genotyping was carried out
using the iPLEX genotyping platform (Sequenom, San
Diego, CA). SNPs that were not in Hardy-Weinberg equi-
librium (P = 0.001) or with a MAF <1% were excluded
from analysis. Patients with greater than 10% missing
genotypes were also excluded. For haplotype association
analysis, PHASE version 2.1.1[25,26] was used to infer
common CRP haplotypes (frequency >5%) for every indi-
vidual.
Statistical analysis
A linear regression model of clinical predictors of postop-
erative plasma CRP levels was constructed. Clinically rele-
vant variables and those with a P = 0.20 on univariate
analysis were entered into the model using stepwise
regression. Variables included in the final model were age,
gender, race, institution, preoperative CRP level, body
mass index (BMI), history of chronic inflammatory dis-
ease of the bowel, joints or skin, current smoker, corticos-
teroid use in the month prior to surgery, HMG-CoA
reductase inhibitor use within 24 hours of surgery andBMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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administration of a homologous blood product during
the perioperative period.
Subsequently, the association between CRP gene variants
and rank-ordered peak postoperative CRP levels was
tested for dominant, additive and recessive genetic mod-
els while adjusting for the variables in the clinical model.
To gain additional insight as to how CRP gene variants
influence the temporal profile of CRP levels on POD 1–4,
CRP measurements were first logit-transformed to
approximate a normal distribution – logit-transformation
is applied over other forms of transformation to map a
bounded variable to the entire real line as is the case with
our CRP measurements. Subsequently a repeated-measure
Tobit regression model[27], adjusted for the above-men-
tioned clinical predictors, was applied to estimate the cen-
sored normal distribution of the transformed CRP levels
while accounting for the correlated observations on differ-
ent postoperative days for all patients. The repeated-meas-
ure Tobit regression model included a random effect to
account for the correlation between repeated measures.
Finally, robust standard errors were computed based on
Huber sandwich estimators to reduce the leverage exerted
by any remaining outlier observation in the parameter
estimation. Taking into account the posterior probabili-
ties of each possible haplotypic pair, inferred CRP haplo-
types were tested for association with CRP levels using the
repeated-measure Tobit regression model with the most
frequent haplotype (H1) as the reference haplotype. A
bootstrapping procedure was applied to estimate the
effect of each minor allele or haplotype on postoperative
plasma CRP levels, and to mitigate the potential for over-
fitting[28,29]. CRP concentrations are presented as medi-
ans with inter-quartile ranges. A P < 0.05 after Bonferroni
correction was considered statistically significant. SAS ver-
sion 9.1.3 (SAS Institute, Cary, NC) was used to build the
clinical model, R Statistical Software was used for
repeated-measure Tobit regression model [30], and
PLINK was used for the peak CRP gene association analy-
sis [31].
Results
After implementing the exclusion criteria, 604 of the orig-
inal 1082 patients were entered into the analysis. Baseline
Table 1: Baseline demographic and clinical characteristics of the 
study population (n = 604)*.
Demographic data
Age at enrollment (Yrs) 65 ± 10
Gender (Male %) 82
Race (Caucasian vs. Other %) 89
Institution A, (%) 79
Preoperative Data
Body mass index (kg/m2) 28.8 ± 4.9
History of diabetes (Types I and II) (%) 28.5
aHistory of peripheral vascular disease (%) 9.7
bHistory of chronic inflammation (%) 16.8
Current smoker (%) 9.3
cPreoperative CRP level (mg/L) 1.2 [0.6–2.8]
Preoperative creatinine (mg/dL) 1.09 ± 0.30
Preoperative Medications
dPreoperative steroid use (%) 2.0
Duration of statin use prior to CABG (%)
No statin use 23.1
<1 month 11.1
1–6 months 8.3
≥ 6 months 43.6
Unknown 13.9
Last statin dose administered prior to CABG (%)
<24 hours 62.1
24–72 hours 5.4
≥ 72 hours 1.3
Unknown 8.1
Preoperative aspirin use (%) 76.3
Intraoperative Data
eBlood product transfusion (%) 56.3
Aortic cross clamp time (min) 73 ± 34
Cardiopulmonary bypass time (min) 98 ± 43
Number of coronary grafts (%)
12 . 8
21 3 . 8
34 4 . 9
≥ 4 38.5
*Continuous data are expressed as mean ± SD. aPeripheral vascular 
disease was defined as vascular disease of the upper or lower 
extremities, or thoracic or abdominal aorta by patient history. 
bChronic inflammation disease of the bowel, joints or skin by patient 
history. cCRP level expressed in median mg/L with 25th and 75th 
percentiles.dSteroids given by any route within the last month. eBlood 
product of any kind given intraoperatively through postoperative day 
2.
Table 1: Baseline demographic and clinical characteristics of the 
study population (n = 604)*. (Continued)BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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demographic and clinical characteristics are shown in
Table 1. Missing pattern analysis on the excluded patients
demonstrated no significant differences, and therefore
were considered missing at random. The median preoper-
ative plasma CRP level was 1.2 mg/L IQR [0.6–2.8 mg/L].
Postoperative plasma CRP levels were significantly ele-
vated at all time points compared with the preoperative
level (P  < 0.0001). Median peak postoperative plasma
CRP level was 293.3 mg/L IQR [153.6–300.0 mg/L],
occurring on POD 2 or 3 in 80.5% of patients. Plasma
CRP levels of ≥300 mg/L were measured immediately
post-CPB and on PODs 1–4 in 0%, 6.5%, 31.1%, 29.8%
and 18.2% of the patients, respectively. Of the nineteen
CRP  SNPs genotyped, two SNPs (rs3093066 and
rs3093058) were excluded for MAFs <1%. The remaining
seventeen  CRP  SNPs survived predefined genotyping
quality control criteria, and were included in subsequent
analysis. CRP SNPs are characterized in Table 2. The link-
age disequilibrium (LD) pattern between genotyped CRP
SNPs is shown in Figure 1. All SNPs were in Hardy-Wein-
berg equilibrium.
Male gender (P = 0.002), increased BMI (P = 0.046) and
perioperative administration of leukocyte-rich blood
Table 2: Candidate CRP gene single nucleotide polymorphisms.
dbSNP rs# Chromosome Position† Nucleotide Position†† Role Minor:Major Allele MAF (%)
rs1572970 chr1:157940209 10691 3' Downstream G:A 0.287
rs876537 chr1:157941557 9343 3' Downstream T:C 0.393
rs876538 chr1:157942341 8559 3' Downstream A:G 0.186
rs2794520 chr1:157945440 5460 3' Downstream T:C 0.337
rs3093077 chr1:157946260 4640 3' Downstream G:T 0.071
rs2808630 chr1:157947492 3408 3' Downstream C:T 0.265
rs1205 chr1:157948857 2043 3'UTR T:C 0.342
rs1130864 chr1:157949715 1185 3'UTR T:C 0.299
rs3093066 chr1:157949723 1177 3'UTR A:C 0.009*
rs1800947 chr1:157950062 838 Coding synonymous C:G 0.071
rs1417938 chr1:157950810 90 Intron A:T 0.296
rs3091244 chr1:157951289 -390 Promotor --- 0.624 (C)
0.301 (T)
0.075 (A)
rs2794521 chr1:157951720 -821 Promotor C:T 0.266
rs3093059 chr1:157951760 -861 Promotor C:T 0.075
rs3093058 chr1:157951939 -1040 Promotor T:A 0.006*
rs3122012 chr1:157955947 -5048 Promotor C:T 0.295
rs2794517 chr1:157959329 -8430 Promotor A:G 0.224
rs3116654 chr1:157962385 -11486 Promotor C:T 0.123
rs3116653 chr1:157963534 -12635 Promotor G:C 0.296
†NCBI hg version 36. ††Nucleotide position given relative to ATG start codon of the CRP gene. The alleles of the triallelic SNP rs3091244 are 
described in the MAF column. *Excluded from further analyses due to minor allele frequency (MAF) <1%.BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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products (P = 0.02) were independently associated with
increased peak postoperative CRP levels based on the clin-
ical regression model. There was no difference in minor
allele frequencies or CRP levels between Caucasians and
non-Caucasians. After adjusting for clinical covariates,
including race, the T allele of rs3091244 was independ-
ently associated with higher peak postoperative CRP lev-
els (P = 2.1 × 10-3), while the minor allele (C) of
rs1800947 was independently associated with lower peak
postoperative CRP levels (P = 2.4 × 10-4) (Table 3). After
adjusting for clinical covariates and repeated CRP meas-
urements using Tobit regression analysis, rs3091244 T
remained independently associated with higher postoper-
ative CRP levels (P = 2.0 × 10-3) and rs1800947 C was
independently associated with lower postoperative CRP
levels (P = 4.8 × 10-5) for dominant genetic models (Table
3). Similar model fitting results were found for these SNPs
with both dominant and additive genetic models (results
not shown). rs1800947 C remained independently asso-
ciated with lower postoperative CRP levels after adjusting
Linkage disequilibrium (LD) pattern for candidate CRP gene single nucleotide polymorphisms (SNPs) Figure 1
Linkage disequilibrium (LD) pattern for candidate CRP gene single nucleotide polymorphisms (SNPs). NCBI hg 
version 36. *The triallelic rs3091244 SNP is presented as one base pair apart. Numbers within the pattern represent the r2 val-
ues, indicating the level of correlation between single nucleotide polymorphisms. SNPs rs3316653, rs3316654, rs2794517, 
rs3122012, rs3093058, rs2808630, rs3093077, rs2794520, rs876538, rs876537, and rs1572970 are tagSNPs selected using 
Haploview's Tagger based on a pairwise r2 tagging threshold of 0.8.BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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for multiple comparisons. Although rs3091244 T was
below the unadjusted level of significance, it achieved
only borderline significance after adjusting for multiple
comparisons.
Four common CRP  haplotypes (frequency ≥ 5%) were
derived from the two most informative CRP  candidate
SNPs, rs1800947 and rs3091244, (Table 4). The overall
joint test of CRP haplotypes on postoperative CRP levels
was highly significant after adjusting for clinical covari-
ates, repeated CRP measurements, and accounting for the
posterior probabilities of each possible haplotypic pair (P
= 7.44 × 10-8). Compared with the GC haplotype (H1, the
most common haplotype), the CC haplotype (H4) was
independently associated with lower postoperative CRP
levels (P = 4.64 × 10-3) whereas GT haplotype (H2) was
associated with higher postoperative CRP levels (P  =
0.029).
Table 3: CRP gene single nucleotide polymorphisms association results for postoperative plasma CRP levels following coronary artery 
bypass graft surgery.
dbSNP rs# Minor Allele β-Coefficient‡ Peak Postoperative
CRP P-value†
Repeated-Measures
Postoperative CRP
P-value††
rs1572970 G -0.124 0.709 0.180
rs876537 T -0.107 0.041 0.272
rs876538 A -0.143 0.606 0.155
rs2794520 T -0.104 0.004 0.058
rs3093077 G -0.056 0.931 0.653
rs2808630 C -0.061 0.898 0.501
rs1205 T -0.180 0.004 0.068
rs1130864 T 0.232 0.011 9.0 × 10-3
rs1800947 C -0.477 2.4 × 10-4*4 . 8  ×  1 0 -5*
rs1417938 C 0.242 0.007 0.006
rs3091244 C -0.218 0.026 0.105
rs3091244 T 0.274 2.1 × 10-3 2.0 × 10-3
rs3091244 A -0.075 0.948 0.529
rs2794521 C -0.059 0.932 0.535
rs3093059 T -0.067 0.986 0.584
rs3122012 C 0.253 0.009 0.007
rs2794517 A 0.057 0.962 0.555
rs3116654 C 0.014 0.567 0.903
rs3116653 G 0.249 0.008 0.005
Results shown for dominant genetic model. ‡Describes associated effect of the minor allele on postoperative CRP levels based on a Tobit 
regression model. The same directional effect was seen for peak postoperative CRP levels. †Using rank-ordered peak postoperative CRP level 
adjusted for clinical covariates. ††Using repeated measures of logit-transformed postoperative CRP level in a Tobit regression model and adjusting 
for clinical covariates. *Below the Bonferroni adjusted level of significance for multiple comparisons.BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
Page 7 of 11
(page number not for citation purposes)
Observed and bootstrapped estimates of the effects of
rs1800947, rs3091244 and H4 on plasma CRP levels
(POD1-4) are shown in Figure 2. The rs1800947 minor
allele was significantly associated with lower plasma CRP
levels on POD2-4 (P ≤ 0.0095), the rs3091244 T allele
was significantly associated with higher plasma CRP levels
on POD2 and 3 (P ≤ 0.0073), and H4 was associated with
lower postoperative plasma CRP levels on POD2-4 (P ≤
0.0037).
Discussion
We investigated the association between 17 candidate
CRP SNPs and perioperative plasma CRP levels in patients
undergoing primary, elective CABG surgery with CPB.
After adjusting for clinical covariates, the minor allele of
the synonymous coding SNP, rs1800947 was associated
with lower peak postoperative CRP levels, and lower CRP
levels across all postoperative time points. Although the
rs3091244 T allele did not survive Bonferroni correction
for multiple comparisons, this CRP  SNP was strongly
associated with elevated postoperative plasma CRP levels
following CABG surgery. Furthermore, these associations
were not influenced by race. In the largest cardiac surgical
cohort study to date to look at CRP polymorphisms, we
provide novel evidence that two CRP gene SNPs inde-
pendently predict postoperative plasma CRP levels fol-
lowing CABG surgery.
The minor allele for the rs1800947 polymorphism has
consistently been associated with lower baseline plasma
CRP levels[16,19,32-36] and decreased prevalence of
CVD-related mortality in ambulatory populations[18,37].
However, the association between CRP gene variants and
postoperative plasma CRP levels is largely unexplored.
Brull et al. sought to test the hypothesis that common CRP
gene variants influence both baseline and postoperative
plasma CRP levels in patients undergoing CABG sur-
gery[38]. Possibly limited by low statistical power, these
authors failed to demonstrate an association between
rs1800947 and increased postoperative CRP levels.
Located on exon 2 of the CRP gene, rs1800947 is a synon-
ymous coding polymorphism. Until recently, it has been
thought that synonymous coding polymorphisms, such
as rs1800947 (CTG [Leu]→CTC [Leu]), do not affect gene
function or phenotype. However, recent evidence suggests
that allele-specific differences in codons can result in
altered post-translational protein folding and func-
tion[39,40]. Nonetheless, without supporting mRNA
expression analyses to further elucidate the functional
effects of the rs1800947 SNP on plasma CRP levels, we
can only speculate as to the functionality of rs1800947.
Alternatively, rs1800947 may be in linkage disequilib-
rium (LD) with a true functional polymorphism; the clos-
est polymorphisms in LD with rs1800947 are rs11265263
(r2 = 0.88) and rs11588887 (r2 = 0.58), 27 kbp and 33.7
kbp in the 5' direction, respectively. Although we were
unable to demonstrate significant LD between rs1800947
and other candidate CRP SNPs in this study, more exten-
sive genotyping would be necessary to fully exclude LD
with surrounding polymorphisms.
rs3091244 is a tri-allelic SNP located in the promotor
region of the CRP gene that has been associated with ele-
vated baseline CRP levels[19,41-44], and increased risk of
coronary artery disease (CAD)[18] in ambulatory
patients. However, no study to date has examined the
association between rs3091244 and postoperative plasma
CRP levels. Located in the second of four identified pro-
motor elements (E-box2) in the CRP  gene promotor
Table 4: Common CRP haplotypes and association results for altered postoperative CRP levels adjusted for clinical covariates 
following coronary artery bypass graft surgery.
Haplotypes rs1800947 rs3091244 Haplotype Frequency Coefficient‡ P-value†
H1 G C 0.56 Reference
H2 G T 0.29 0.21* 0.029
H3 G A 0.07 -0.03 0.771
H4 C C 0.06 -0.36* 4.64 × 10-3
H Other -- -- 0.02 -0.56 0.808
Results are shown for dominant genetic model. Major and minor alleles, and forward/bottom strand orientation according to NCBI hg version 36 
for Caucasian populations. CRP SNPs in strong linkage disequilibrium are combined; therefore not all genotyped SNPs are represented. ‡Describes 
associated effect of each haplotype on postoperative CRP levels based on a Tobit regression model. †Taking into account posterior probabilities, 
the overall joint test for the haplotype block adjusted for clinical covariates and repeated measures for postoperative CRP was significant at P = 7.44 
× 10-8. *The CC haplotype was significantly associated with decreased postoperative CRP levels at P = 4.64 × 10-3 whereas the GT haplotype was 
associated with increased postoperative CRP levels at P = 0.029.BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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Observed and estimated genetic associations of rs1800947, rs3091244 T and Haplotype 4 with postoperative plasma CRP lev- els Figure 2
Observed and estimated genetic associations of rs1800947, rs3091244 T and Haplotype 4 with postoperative 
plasma CRP levels. Box plot results are presented for the dominant genetic model. Dark gray denotes null copy, light gray 
denotes the minor allele of rs180094, rs3091244 T allele and CC haplotype (H4). Column A. Observed genetic effect on 
postoperative CRP levels. rs1800947 minor allele and H4 were associated with lower plasma CRP levels (POD2-4 P ≤ 0.0095 
and P ≤ 0.0037, respectively), rs3091244 T allele was associated with higher plasma CRP levels (POD2 and 3 P ≤ 0.0073). Col-
umn B. Bootstrapping estimates for CRP levels using repeated-measure Tobit regression model adjusted for clinical covari-
ates.
A. B.
rs1800947C rs1800947C
rs3091244T rs3091244T
H4 H4BMC Medical Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2350/10/38
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region, Szalai et al. recently demonstrated that rs3091244
affects promotor activity in vitro by altering transcription
factor binding sites[45]. Alternatively, rs3091244 may be
a marker allele for a true functional CRP gene variant as it
is highly correlated with rs3116653, rs3122012,
rs1417938 and rs1130864 (r2 ≥ 0.93). Of note, rs3091244
is in strong LD with rs1130864 (r2 ≥ 0.94), the CRP poly-
morphism described by Brull et al. as having a similar
effect on postoperative plasma CRP levels in patients
undergoing CABG surgery[38]. Further investigation is
warranted to determine the importance of rs3091244 in
regulating baseline and possibly the postoperative acute-
phase rise plasma CRP levels.
The results of our CRP haplotype analysis are consistent
with our SNP analysis findings. Our result suggests that
compared with the GC haplotype (H1), the CC haplotype
(H4) was significantly associated with decreased postop-
erative plasma CRP levels and the GT haplotype (H2) with
increased CRP levels. Furthermore, the effect size of the
CC haplotype (H4) appeared larger than that of the GT
haplotype (H2). This would correspond to two independ-
ent modifying effects of the rs1800947C (decrease) and
rs3091244T (increase) alleles, consistent with the SNP
association findings from Table 3 as H4 was tagged by
rs1800947C allele and, H2 tagged by the rs3091244T
allele. As such, the results of our haplotype analysis add
little additional information to our SNP association find-
ings.
Several limitations in this study warrant consideration.
Based on a similar study design, we truncated our plasma
CRP measurement at 300 mg/L [38]. In an effort to
approximate normal distribution, we logit-transformed
the left-skewed postoperative CRP distribution, and
applied a Tobit regression to recover the truncated CRP
levels. Despite estimated median postoperative CRP levels
below 300 mg/L in both groups, the effects of CRP gene
variants on postoperative plasma CRP levels were large
enough to be statistically significant. If we assume that
many of the patients with truncated postoperative plasma
CRP levels of 300 mg/L in fact had levels greater than 300
mg/L, then our results may in fact underestimate the sig-
nificance of the association between CRP gene variants
and postoperative CRP levels after CABG surgery. Genetic
association testing of multiple SNPs to CRP levels at many
time points in a large sample population also introduces
the potential for false positive findings as a result of mul-
tiple testing and over-fitting. After applying the Bonfer-
roni correction to address multiple tests of statistical
significance, the rs1800947 remained significantly corre-
lated with altered postoperative plasma CRP levels. While
rs3091244 did not survive Bonferroni correction, based
on prior studies, we believe its biological significance
deserves consideration in future investigations. Inherent
bias within the sample population can lead to overfitting
and false positive results. Bootstrapping is a statistical re-
sampling procedure that alleviates the potential for model
overfitting by eliminating bias. Our results show that after
applying the bootstrapping procedure, the effect of the
genetic variants on postoperative plasma CRP levels
remained significantly different, therefore making overfit-
ting unlikely. Finally, recently published results from
genome-wide association studies suggest that additional
proinflammatory genes (GCKR,  HNF1A,  LEPR,  IL6R,
APOE) influence baseline plasma CRP levels in ambula-
tory populations[20,21]. It is likely therefore, that a
number of genes or a combination thereof, may also
influence the acute-phase rise in CRP levels.
Conclusion
Emerging evidence that CRP gene variants associated with
elevated baseline plasma CRP levels[16,32,36,41] are her-
itable [14-16]. We submit that the acute-phase rise in
postoperative plasma CRP levels after CABG surgery is
influenced by CRP gene variants. Further investigation is
needed to clarify the significance of the association
between CRP gene variants and the acute-phase rise in
postoperative CRP levels with regard to the risk of adverse
perioperative outcomes.
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